Media Summary: Hear more from CEO Daniel O’Day about Gilead Sciences' investment in U.S. innovation. PhRMA and senior executives and researchers from four member companies met with key policy makers on Capitol Hill to discuss ... Paulo shares how he's running and thankful for the people who supported him during his month-long hospital stay from

Daniel O Day Of Gilead Sciences Inc On Covid 19 Efforts - Detailed Analysis & Overview

Hear more from CEO Daniel O’Day about Gilead Sciences' investment in U.S. innovation. PhRMA and senior executives and researchers from four member companies met with key policy makers on Capitol Hill to discuss ... Paulo shares how he's running and thankful for the people who supported him during his month-long hospital stay from

Photo Gallery

Daniel O’Day of Gilead Sciences, Inc. on COVID-19 Efforts
Gilead CEO Daniel O'Day on remdesivir pricing and ensuring access to treatment
Gilead Sciences CEO Daniel O'Day: We have the most robust pipeline in company history
Gilead Sciences CEO Daniel O'Day Remarks at 2019 World AIDS Day Observances
President Trump & Gilead CEO Daniel O'Day on emergency FDA approval of Remdesivir
Grand Keynote I Daniel O'Day, Gilead  Sciences Inc and Rich Karlgaard I TiEcon 2021
Gilead's moving quickly with FDA for approval of coronavirus drug remdesivir: CEO
Gilead CEO on treating Covid-19: 'We're not finished with remdesivir'
Hear more from CEO Daniel O’Day about Gilead Sciences' investment in U.S. innovation.
Gilead CEO: We can manufacture enough remdesivir to provide all of the U.S.
Gilead CEO on promising study results for remdesivir Covid-19 treatment
A lot of focus on Gilead has moved beyond Covid-19: Analyst
Sponsored
Sponsored
View Detailed Profile
Daniel O’Day of Gilead Sciences, Inc. on COVID-19 Efforts

Daniel O’Day of Gilead Sciences, Inc. on COVID-19 Efforts

In a

Gilead CEO Daniel O'Day on remdesivir pricing and ensuring access to treatment

Gilead CEO Daniel O'Day on remdesivir pricing and ensuring access to treatment

Gilead Sciences

Sponsored
Gilead Sciences CEO Daniel O'Day: We have the most robust pipeline in company history

Gilead Sciences CEO Daniel O'Day: We have the most robust pipeline in company history

Daniel O

Gilead Sciences CEO Daniel O'Day Remarks at 2019 World AIDS Day Observances

Gilead Sciences CEO Daniel O'Day Remarks at 2019 World AIDS Day Observances

National AIDS Memorial World AIDS

President Trump & Gilead CEO Daniel O'Day on emergency FDA approval of Remdesivir

President Trump & Gilead CEO Daniel O'Day on emergency FDA approval of Remdesivir

Coronavirus

Sponsored
Grand Keynote I Daniel O'Day, Gilead  Sciences Inc and Rich Karlgaard I TiEcon 2021

Grand Keynote I Daniel O'Day, Gilead Sciences Inc and Rich Karlgaard I TiEcon 2021

Grand Keynote at TiEcon 2021 with

Gilead's moving quickly with FDA for approval of coronavirus drug remdesivir: CEO

Gilead's moving quickly with FDA for approval of coronavirus drug remdesivir: CEO

Gilead Sciences

Gilead CEO on treating Covid-19: 'We're not finished with remdesivir'

Gilead CEO on treating Covid-19: 'We're not finished with remdesivir'

Daniel O

Hear more from CEO Daniel O’Day about Gilead Sciences' investment in U.S. innovation.

Hear more from CEO Daniel O’Day about Gilead Sciences' investment in U.S. innovation.

Hear more from CEO Daniel O’Day about Gilead Sciences' investment in U.S. innovation.

Gilead CEO: We can manufacture enough remdesivir to provide all of the U.S.

Gilead CEO: We can manufacture enough remdesivir to provide all of the U.S.

Gilead Sciences

Gilead CEO on promising study results for remdesivir Covid-19 treatment

Gilead CEO on promising study results for remdesivir Covid-19 treatment

Gilead Sciences

A lot of focus on Gilead has moved beyond Covid-19: Analyst

A lot of focus on Gilead has moved beyond Covid-19: Analyst

Gilead

Biopharmaceutical Response to COVID-19

Biopharmaceutical Response to COVID-19

PhRMA and senior executives and researchers from four member companies met with key policy makers on Capitol Hill to discuss ...

Gilead Sciences CEO Daniel O'Day on the collaboration with biotech firm Galapagos

Gilead Sciences CEO Daniel O'Day on the collaboration with biotech firm Galapagos

Gilead Sciences

Gilead CEO Daniel O'Day on acquisition of cancer drugmaker Immunomedics

Gilead CEO Daniel O'Day on acquisition of cancer drugmaker Immunomedics

Gilead Sciences

Gilead CEO: Oral version of Covid drug Remdesivir in early testing

Gilead CEO: Oral version of Covid drug Remdesivir in early testing

Gilead

Gilead CEO Daniel O'Day: Ending the HIV epidemic is our goal

Gilead CEO Daniel O'Day: Ending the HIV epidemic is our goal

Gilead

Gilead CEO says coronavirus drug remdesivir could reach patients within days

Gilead CEO says coronavirus drug remdesivir could reach patients within days

Daniel O

Working to combat COVID-19

Working to combat COVID-19

PhRMA and senior executives and researchers from four member companies met with key policy makers on Capitol Hill to discuss ...

The Journey to Run Again After Beating COVID-19: Paulo’s Story

The Journey to Run Again After Beating COVID-19: Paulo’s Story

Paulo shares how he's running and thankful for the people who supported him during his month-long hospital stay from